We are live on
!
Find out more
PA
Perceptive Advisors Portfolio holdings
AUM
$6.66B
1-Year Est. Return
360.84%
This Fund
S&P 500
This Quarter
Est. Return
+37.79%
1 Year Est. Return
+360.84%
3 Year Est. Return
+1,707.27%
5 Year Est. Return
+3,210.42%
10 Year Est. Return
+53,055.89%
AUM
$2.62B
AUM Growth
+$630M
(+32%)
Cap. Flow
+$142M
Cap. Flow
% of AUM
5.42%
Top 10 Holdings %
Top 10 Hldgs %
54.13%
Holding
172
New
46
Increased
29
Reduced
19
Closed
33
Avg Time Held Equity + Options
4.2
quarters
Top 10 Avg Time Held Equity + Options
5.4
quarters
Top 20 Avg Time Held Equity + Options
5.4
quarters
Avg Time Held Equity only
4.4
quarters
Top 10 Avg Time Held Equity only
5.4
quarters
Top 20 Avg Time Held Equity only
5.5
quarters
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Neurocrine Biosciences
NBIX
|
+$64.1M |
| 2 |
AVXS
AveXis, Inc. Common Stock
AVXS
|
+$36.1M |
| 3 |
XLRN
Acceleron Pharma
XLRN
|
+$31.4M |
| 4 |
Puma Biotechnology
PBYI
|
+$17.7M |
| 5 |
Cymabay Therapeutics
CBAY
|
+$15.9M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ARAV
Aravive, Inc. Common Stock
ARAV
|
+$42.4M |
| 2 |
Sarepta Therapeutics
SRPT
|
+$36.7M |
| 3 |
Radius Health, Inc.
RDUS
|
+$29.2M |
| 4 |
Vertex Pharmaceuticals
VRTX
|
+$20.9M |
| 5 |
Jazz Pharmaceuticals
JAZZ
|
+$13.3M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 98.22% |
| 2 | Miscellaneous | 1.22% |
| 3 | Industrials | 0.33% |
| 4 | Consumer Staples | 0.16% |
| 5 | Consumer Discretionary | 0.07% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
IVC
76
DELISTED
Invacare Corporation
IVC
| $3.95M | 0.15% |
+200,000
| New | +$2.86M |
2017 Q3
0 quarters
|
|
|
GWPH
77
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
| $3.73M | 0.14% |
+36,763
| New | +$3.94M |
2017 Q3
0 quarters
|
|
78
NuCana
NCNA
$4.49M
| $3.67M | 0.14% |
+40
| New | +$3.45M |
2017 Q3
0 quarters
|
|
79
Ocugen
OCGN
$321M
| $3.52M | 0.13% |
29,630
| – | – |
2016 Q3
4 quarters
|
|
80
Repligen
RGEN
$11B
| $3.35M | 0.13% |
+87,400
| New | +$3.66M |
2017 Q3
0 quarters
|
|
81
Gilead Sciences
GILD
$187B
| $3.24M | 0.12% |
+40,000
| New | +$3.06M |
2017 Q3
0 quarters
|
|
|
VRNA
82
DELISTED
Verona Pharma
VRNA
| $3.07M | 0.12% |
200,000
| – | – |
2017 Q2
1 quarter
|
|
83
Corbus Pharmaceuticals
CRBP
$102M
| $2.96M | 0.11% |
13,823
-27,260
| -66% | -$5.33M |
2015 Q2
9 quarters
|
|
84
PUT
DBV Technologies S.A. American Depositary Shares
DBVT
$600M
| $2.81M | 0.11% |
+55,000
| New | +$23.6M |
2017 Q3
0 quarters
|
|
|
PFNX
85
DELISTED
Pfenex Inc.
PFNX
| $2.56M | 0.1% |
845,973
| – | – |
2014 Q3
12 quarters
|
|
|
VIVE
86
DELISTED
VIVEVE MED INC
VIVE
| $2.55M | 0.1% |
487
-403
| -45% | -$2.48M |
2017 Q1
2 quarters
|
|
|
OCRX
87
DELISTED
Ocera Therapeutics, Inc.
OCRX
| $2.32M | 0.09% |
2,038,880
| – | – |
2017 Q1
2 quarters
|
|
88
CALL
Alnylam Pharmaceuticals
ALNY
$30.4B
| $2.31M | 0.09% |
+100,000
| New | +$8.54M |
2017 Q3
0 quarters
|
|
|
MGCD
89
DELISTED
MGC Diagnostics Corporation
MGCD
| $2.26M | 0.09% |
252,327
| – | – |
2013 Q2
17 quarters
|
|
90
ADMA Biologics
ADMA
$2.28B
| $2.22M | 0.08% |
721,102
| – | – |
2016 Q3
4 quarters
|
|
91
Seres Therapeutics
MCRB
$26.9M
| $2.17M | 0.08% |
+6,750
| New | +$1.84M |
2017 Q3
0 quarters
|
|
92
Abeona Therapeutics
ABEO
$280M
| $1.99M | 0.08% |
4,676
-12,239
| -72% | -$3.29M |
2014 Q4
11 quarters
|
|
93
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
| $1.95M | 0.07% |
+102,500
| New | +$1.88M |
2017 Q3
0 quarters
|
|
|
EIGR
94
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
| $1.73M | 0.07% |
5,256
| – | – |
2016 Q1
6 quarters
|
|
95
DELISTED
BRAINSTORM CELL THERAPUTC
BCLI
| $1.65M | 0.06% |
26,667
| – | – |
2017 Q2
1 quarter
|
|
96
DELISTED
Affimed
AFMD
| $1.5M | 0.06% |
66,821
| – | – |
2016 Q2
5 quarters
|
|
97
Champions Oncology
CSBR
$68.9M
| $1.42M | 0.05% |
386,540
+19,567
| +5% | +$59.9K |
2015 Q3
8 quarters
|
|
98
Curis
CRIS
$1.56M
| $1.42M | 0.05% |
476
| – | – |
2017 Q1
2 quarters
|
|
|
ZYNE
99
DELISTED
Zynerba Pharmaceuticals, Inc
ZYNE
| $1.32M | 0.05% |
+130,700
| New | +$1.38M |
2017 Q3
0 quarters
|
|
100
OraSure Technologies
OSUR
$270M
| $1.23M | 0.05% |
54,729
| – | – |
2017 Q1
2 quarters
|
|
Similar funds
QP
FCBT
RWM
AWA
WHRC
KGA
LSERS
CAG
Perceptive Advisors's Q3 2017 Portfolio in Review
As of Q3 2017, Perceptive Advisors held 172 positions worth $2.62B, up 32% from $1.99B the previous quarter. Its ten largest holdings account for 54% of the portfolio.
Perceptive Advisors deployed $142M of net new capital in Q3 2017, opening 46 new positions and adding to 29 existing holdings. Its largest new stake was Cymabay Therapeutics: 2,350,882 shares worth $18.9M.
By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 96% a quarter earlier, followed by Miscellaneous and Industrials.
On the sell side, the largest reduction was Aravive, Inc. Common Stock, an estimated $42.4M trimmed.
- Perceptive Advisors's largest Q3 2017 buy was Cymabay Therapeutics: 2,350,882 shares worth $18.9M.
- Perceptive Advisors added most to Neurocrine Biosciences in Q3 2017, an estimated $64.1M increase.
- Perceptive Advisors's biggest Q3 2017 reduction was Aravive, Inc. Common Stock, cutting an estimated $42.4M.
- Perceptive Advisors fully exited Sarepta Therapeutics in Q3 2017, selling an estimated $36.7M.
- Perceptive Advisors's ten largest holdings make up 54% of its $2.62B portfolio in Q3 2017.
- Perceptive Advisors opened 46 new positions and closed 33 in Q3 2017.
- Perceptive Advisors's portfolio value rose 32% quarter-over-quarter to $2.62B.
Based on Perceptive Advisors's 13F filing for Q3 2017, filed 14 Nov 2017.